K B McCredie
Overview
Explore the profile of K B McCredie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
293
Citations
1921
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keating M, Hester J, McCredie K, Burgess M, Murphy W, Freireich E
Leuk Lymphoma
. 2016 Jul;
2(6):391-7.
PMID: 27457043
This study was designed to study the efficacy and toxicity of an adriamycin-containing regimen (CAP: cyclophosphamide, adriamycin, and prednisone) in patients with previously untreated chronic lymphocytic leukemia (CLL). CAP was...
2.
Hester J, Kellogg R, Mulzet A, Kruger V, McCredie K, Freireich E
Ther Apher
. 2000 May;
4(2):98-107.
PMID: 10805427
No abstract available.
3.
Kantarjian H, Talpaz M, OBrien S, Kurzrock R, Gutterman J, Keating M, et al.
Clin Cancer Res
. 1999 Mar;
3(12 Pt 2):2723-33.
PMID: 10068280
The purpose of this study was to review the progress in clinical and translational research in chronic myelogenous leukemia (CML) over the past 20 years at M.D. Anderson Cancer Center....
4.
Guo J, Xian Y, Stass S, Champlin R, Giralt S, McCredie K, et al.
Hematol Pathol
. 1993 Jan;
7(2):91-106.
PMID: 8340287
The benign phase of chronic myelogenous leukemia (CML) typically is characterized by an overproduction of myeloid cells that eventually progresses to a more acute stage termed blast crisis. This latter...
5.
Freireich E, Cork A, Stass S, McCredie K, Keating M, Estey E, et al.
Leukemia
. 1992 Jun;
6(6):500-6.
PMID: 1602788
Bone marrow samples collected from acute myeloblastic leukemia (AML) patients in complete clinical and hematological remission were studied for the persistence of cytogenetic abnormalities. AML patients from the three favorable...
6.
Estey E, Kurzrock R, Kantarjian H, OBrien S, McCredie K, Beran M, et al.
Blood
. 1992 Feb;
79(4):882-7.
PMID: 1346577
We administered one course of 2-chlorodeoxyadenosine (2CdA) at 4 mg/m2 daily for 7 days by continuous intravenous infusion to 46 patients with hairy cell leukemia. Complete remissions occurred in 36...
7.
Kantarjian H, Talpaz M, Keating M, Estey E, OBrien S, Beran M, et al.
Cancer
. 1991 Sep;
68(6):1201-7.
PMID: 1873771
In a pilot study, 32 patients with Philadelphia chromosome-positive chronic myelogenous leukemia were treated with intensive chemotherapy induction followed by interferon-alpha (IFN-A) maintenance. Intensive chemotherapy consisted of three cycles of...
8.
Estey E, Kurzrock R, Talpaz M, McCredie K, OBrien S, Kantarjian H, et al.
Br J Haematol
. 1991 Mar;
77(3):291-5.
PMID: 2012752
There has been no previously published experience with granulocyte-macrophage colony stimulating factor (GM-CSF) doses less than 12 micrograms/m2 daily in patients with myelodysplastic syndromes, and most observations have been made...
9.
Lotzova E, Savary C, Totpal K, Schachner J, Lichtiger B, McCredie K, et al.
Leuk Res
. 1991 Jan;
15(4):245-54.
PMID: 2030606
We have generated and characterized a highly oncolytic adherent lymphocyte subset (A-LAK) from eight leukemic patients with non-lymphocytic leukemia (NLL) in remission and one NLL patient in relapse. Our studies...
10.
DREIZEN S, Menkin D, Keating M, McCredie K, ONeill P
Oral Surg Oral Med Oral Pathol
. 1991 Jan;
71(1):45-9.
PMID: 1994322
This study was designed to elicit the effects of antileukemia chemotherapy on marrow production, blood carriage, and oral extravasation of granulocytes, and on the phagocytic activity of those harvested from...